NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/07/2025
Back to search
Official data from USPTO
ARETEIA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ARETEIA THERAPEUTICS
ST13
US500000097612596Class
5
Filing
97612596
Registration
7645073
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
01/07/2025
Trademark type
Word
Nice classes
5
Filing date
09/29/2022
Registration date
01/07/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/07/2025
Last transaction
01/07/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/28/2024
First use in commerce
06/28/2024
Drawing code
4
Owner type
03
Owner location
Chapel Hill, NC
Examiner
ROTH, BENJAMIN
Law office
N40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Areteia Therapeutics, Inc.
Representatives
Emilia F. Cannella ROPES & GRAY LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment and prevention of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
24 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/07/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/17/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/17/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/23/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/21/2024
IUAF
USE AMENDMENT FILED
09/17/2024
EISU
TEAS STATEMENT OF USE RECEIVED
09/17/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
04/11/2024
EX1G
SOU EXTENSION 1 GRANTED
04/10/2024
EXT1
SOU EXTENSION 1 FILED
04/10/2024
EEXT
SOU TEAS EXTENSION RECEIVED
04/10/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/17/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/22/2023
PUBO
PUBLISHED FOR OPPOSITION
08/22/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/17/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
07/17/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/17/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
07/17/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/17/2023
DOCK
ASSIGNED TO EXAMINER
07/13/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/03/2022
NWAP
NEW APPLICATION ENTERED
10/03/2022
Continuous trademark protection
Get notified about every new filing that threatens ARETEIA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.